Cloud-based technologies, big data, statistical signal processing algorithms, and Artificial Intelligence (AI) technologies are expected to play an increasingly important role in themedical field. Big data and AI-technologies rely on the cloud for data storage as well as for computational power and thus need effective and robust legal frameworks for international data transfer. Because of inconsis

In this two-part paper, influences from environmental factors on lightning in a convective storm are assessed with a model. In Part I, an electrical component is described and applied in the Aerosol-Cloud model (AC). AC treats many types of secondary (e.g., breakup in ice-ice collisions, raindrop-freezing fragmentation, rime splintering) and primary (heterogeneous, homogeneous freezing) ice initia

Over twenty years after the Universal Declaration on the Human Genome and Human Rights alerted the international community of the need to prevent discriminatory use of genetic information, it still remains a pervasive issue. Legal efforts to address genetic discrimination (GD) solely at the national level are unlikely to resolve a problem that now transcends national frontiers. People should have

The pharmaceutical and healthcare sector is a prime target for cybercriminals around the world. These cyber-attacks represent significant challenges in the context of data protection and data security. The General Data Protection Regulation (GDPR) imposes strict rules regarding the processing and analysis of personal data. In conventional approaches, data analysts request data from various sources

Multiple factors indicate that big data, artificial intelligence and machine learning will play a crucial role in the evolution of pharmaceutical innovation.The ongoing paradigm shift is fuelled by rapid technical advances that have greatly transformed and enhanced many facets of the pharmaceutical sector. Huge datasets are driving new drug discoveries and are making clinical trials more efficient

This is a review of the recent publication “Pharmaceutical Innovation, Competition and Patent Law – A Trilateral Perspective”, edited by Max Planck Director Josef Drexl and Finnish scholar Nari Lee (Edward Elgar 2013, 322 p., ISBN 978 0 85793 245 7). In summary, I conclude that the editors, who also contributed with excellent papers, have succeeded very well in the difficult task of structuring, s

While greater incentives and new funding models for antibiotic drug develooment are needed, it is unclear whether a system dependent on endlessly churning out new and ever more expensive medicines will be economically feasible and scientifically possible in the long term. Greater priority should therefore be given to implementing more permanent solutions that are not limited to slowing resistance,

The novel coronavirus (COVID-19) is challenging the world. With no vaccine and limited medical capacity to treat the disease, nonpharmaceutical interventions (NPI) are the main strategy to contain the pandemic. Unprecedented global travel restrictions and stay-at-home orders are causing the most severe disruption of the global economy since World War II. With international travel bans affecting ov